0001193125-26-380191 | 10-Q | XBRL Viewer

Print Document

Balance Sheet Components -Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Balance Sheet Related Disclosures [Abstract]
Accrued compensation	$ 2,890	$ 4,365
Accrued expenses	2,414	1,974
Government grant liability	1,792	0
Accrued taxes	87	0
Other current liabilities	0	66
Total	$ 7,183	$ 6,405

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2026

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of significant accounting policies

Basis of Preparation

The accompanying condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The condensed financial statements were also prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the ordinary course of business. Since inception, the Company has not generated any product revenue, and its operations have primarily consisted of establishing facilities, recruiting personnel, conducting research and development, and raising capital. Certain information and footnote disclosures normally included in the condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with such rules and regulations.

The significant accounting policies and estimates used in the preparation of these financial statements are consistent with those described in the Company’s audited financial statements for the year ended December 31, 2025. During the current interim period, there have been no material changes to these policies.

Reclassifications

Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the Company's total assets, total liabilities, stockholders' equity, net loss, comprehensive

income (loss) or cash flows.

Reverse Stock Split

On July 17, 2026, the Company amended its amended and restated certificate of incorporation and effected a 5.9218-for-1 reverse stock split of its issued and outstanding common stock (the “Reverse Stock Split”). Accordingly, every 5.9218 shares of common stock were combined into one share of common stock. Fractional shares resulting from the Reverse Stock Split were rounded in accordance with the terms of the amendment to the Company’s certificate of incorporation.

All common stock share amounts, stock option and warrant shares, conversion ratios, shares reserved for future issuance, net loss per share, and other per share information presented in the accompanying financial statements and notes thereto have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented. The par value of the Company’s common stock was not affected by the Reverse Stock Split.

Use of Estimates

The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to revenue recognition, lease liabilities, fair value of redeemable convertible preferred stock and common stock, stock-based compensation expense, accruals for research and development costs, the valuations of deferred tax assets, the fair value of the convertible note and uncertain income tax positions. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.

Government Grants

The Company accounts for government grants received by business entities in accordance with ASC 832, Government Grants. Government grants are recognized when it is probable that the Company will comply with the conditions attached to the grant and that the grant will be received. Grants related to income are recognized on a systematic and rational basis over the periods in which the Company recognizes the related costs as expenses.

The Company has determined that its grants awarded by the California Institute for Regenerative Medicine ("CIRM") are grants related to income because the grants are intended to reimburse qualifying research and development expenditures and are not conditioned upon the acquisition or construction of long-lived assets. The Company has elected to present amounts recognized in earnings as a reduction of research and development expense in the condensed statements of operations.

Cash received in advance of incurring qualifying expenditures is recorded as a government grant liability within accrued expenses and other current liabilities. Grant receivables are recorded when qualifying expenditures have been incurred and collection is probable. Grant amounts are recognized only when the Company concludes it is probable that all applicable grant conditions will be satisfied and the grant proceeds will be received.

Recently Adopted Accounting Pronouncements

In September 2025, the FASB issued ASU 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract. The amendments refine the scope of derivative accounting by excluding contracts or embedded features whose settlement amounts are based on the operations or activities specific to one of the parties to the contract and clarify the accounting for share-based noncash consideration received from a customer in a revenue contract. The Company early adopted ASU 2025-07 effective January 1, 2026. The adoption did not have a material impact on the Company's condensed financial statements.

In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which establishes recognition, measurement, presentation and disclosure requirements for government grants received by business entities. Under the guidance, a government grant is recognized when it is probable that the entity will comply with the conditions attached to the grant and that the grant will be received. The Company early adopted ASU 2025-10 effective January 1, 2026 using the modified prospective transition method. The Company adopted the guidance in connection with grants awarded by the California Institute for Regenerative Medicine ("CIRM") and accounts for such grants as income-related government grants under ASC 832. The Company elected to present grant amounts recognized in earnings as a reduction of research and development expense. The adoption of the standard did not have a material impact on the Company's condensed financial statements other than the establishment of accounting policies and related disclosures for government grants.

Recently Issued Accounting Pronouncements Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which introduces new disclosure requirements to disaggregate certain natural expenses underlying income statement captions. ASU 2024-03 is effective for annual periods in fiscal years beginning after December 15, 2026, and for interim periods thereafter. Early adoption is permitted. The application of ASU 2024-03 is prospective for periods beginning after the effective date, although retrospective application to prior periods is allowed. The Company is currently assessing the impact that ASU 2024-03 will have on its condensed financial statements and disclosures.

Concentration of Credit Risk

The Company recognized revenue from collaboration partners in the three and six months ended June 30, 2026 and 2025, with all revenue generated within the United States. The percentages of collaboration revenue and accounts receivable from each of the Company’s customers that individually accounted for 10% or more of its total collaboration revenue and accounts receivable were as follows:


	Accounts Receivable, net						Revenue						Revenue
	As of June 30,			As of December 31,			Three Months Ended June 30,						For the Six Months Ended June 30,
	2026			2025			2026			2025			2026			2025
Prevail		96	%		98	%		100	%		98	%		100	%		98	%

As of June 30, 2026 and December 31, 2025, the Company reported no contract assets. The Company routinely assesses its accounts receivable and contract assets for potential impairment and credit losses. As of June 30, 2026 and December 31, 2025, no impairment or credit loss allowance was recorded, respectively.

Unaudited Interim Financial Information

The accompanying condensed financial statements as of June 30, 2026, and for the three and six months ended June 30, 2026 and 2025, are unaudited. The condensed balance sheet as of December 31, 2025 was derived from the Company’s audited financial statements included in the Company's final prospectus filed with the Securities and Exchange Commission on July 24, 2026 pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended. The unaudited interim condensed financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2026, and the results of its operations and its cash flows for the three and six months ended June 30, 2026 and 2025. The results for the three and six months ended June 30, 2026 are not necessarily indicative of the results to be expected for the full year ending December 31, 2026, or for any other future period. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and related notes for the year ended December 31, 2025, included in the Company's final prospectus filed with the Securities and Exchange Commission on July 24, 2026 pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended.

Business Organization and Liquidity	6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]
Business Organization and Liquidity	1. Business Organization and Liquidity Scribe Therapeutics Inc. (the “Company”) is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. The Company was incorporated in the state of Delaware in June 2017. Its principal offices are in Alameda, California. Liquidity and Going Concern The accompanying unaudited condensed financial statements have been prepared under the assumption that the Company will continue as a going concern. Since inception, the Company has devoted substantially all of its efforts to research and development activities, establishing and protecting its intellectual property, recruiting personnel, raising capital and conducting business planning. The Company has funded its operations primarily through proceeds received from collaboration and license agreements and the issuance of redeemable convertible preferred stock. As of June 30, 2026, the Company had cash, cash equivalents and available-for-sale investments of $43.0 million. The Company has incurred recurring losses and negative cash flows from operations since inception. Net losses were $23.8 million and $13.3 million for the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, the Company had an accumulated deficit of $181.5 million. On July 27, 2026, the Company completed its initial public offering ("IPO") of 9,867,000 shares of common stock, which included the full exercise by the underwriters of their option to purchase an additional 1,287,000 shares, at a public offering price of $15.00 per share. Gross proceeds from the IPO were approximately $148.0 million, before underwriting discounts, commissions and offering expenses. Concurrently with the IPO, the Company completed a private placement of 500,000 shares of common stock to an affiliate of Sanofi at a price of $15.00 per share, resulting in gross proceeds of $7.5 million. In aggregate, the IPO and concurrent private placement generated approximately $155.5 million of gross proceeds. After deducting underwriting discounts, commissions and other offering costs, the Company received net proceeds of approximately $140.7 million from the IPO and concurrent private placement. The Company believes that its existing cash, cash equivalents and available-for-sale investments, together with the net proceeds from the IPO and the concurrent private placement, will be sufficient to fund its planned operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements. Accordingly, management concluded that the substantial doubt about the Company's ability to continue as a going concern that existed as of June 30, 2026 was alleviated prior to the issuance of these financial statements as a result of the completion of the IPO and concurrent private placement.

Business Organization and Liquidity

6 Months Ended

Jun. 30, 2026

Accounting Policies [Abstract]

Business Organization and Liquidity

1. Business Organization and Liquidity

Scribe Therapeutics Inc. (the “Company”) is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. The Company was incorporated in the state of Delaware in June 2017. Its principal offices are in Alameda, California.

Liquidity and Going Concern

The accompanying unaudited condensed financial statements have been prepared under the assumption that the Company will continue as a going concern.

Since inception, the Company has devoted substantially all of its efforts to research and development activities, establishing and protecting its intellectual property, recruiting personnel, raising capital and conducting business planning. The Company has funded its operations primarily through proceeds received from collaboration and license agreements and the issuance of redeemable convertible preferred stock.

As of June 30, 2026, the Company had cash, cash equivalents and available-for-sale investments of $43.0 million. The Company has incurred recurring losses and negative cash flows from operations since inception. Net losses were $23.8 million and $13.3 million for the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, the Company had an accumulated deficit of $181.5 million.

On July 27, 2026, the Company completed its initial public offering ("IPO") of 9,867,000 shares of common stock, which included the full exercise by the underwriters of their option to purchase an additional 1,287,000 shares, at a public offering price of $15.00 per share. Gross proceeds from the IPO were approximately $148.0 million, before underwriting discounts, commissions and offering expenses. Concurrently with the IPO, the Company completed a private placement of 500,000 shares of common stock to an affiliate of Sanofi at a price of $15.00 per share, resulting in gross proceeds of $7.5 million. In aggregate, the IPO and concurrent private placement generated approximately $155.5 million of gross proceeds.

After deducting underwriting discounts, commissions and other offering costs, the Company received net proceeds of approximately $140.7 million from the IPO and concurrent private placement. The Company believes that its existing cash, cash equivalents and available-for-sale investments, together with the net proceeds from the IPO and the concurrent private placement, will be sufficient to fund its planned operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.

Accordingly, management concluded that the substantial doubt about the Company's ability to continue as a going concern that existed as of June 30, 2026 was alleviated prior to the issuance of these financial statements as a result of the completion of the IPO and concurrent private placement.

Net Loss Per Share Attributable to Common Stockholders - Summary of Anti-dilutive Security not Included In Diluted per Share Calculations (Parenthetical) (Details) - $ / shares	Jun. 30, 2026	Dec. 31, 2025	Jun. 30, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, par value	$ 0.001	$ 0.001
Initial Public Offering
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, par value	$ 35.83		$ 35.83

Collaboration and License Agreements - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses	$ 8,823,000	$ 13,884,000	$ 20,128,000	$ 29,876,000
Accrued and other current liabilities	7,183,000		7,183,000		$ 6,405,000
Revenue	1,918,000	4,898,000	4,151,000	22,023,000
Short-term deferred revenue	27,475,000		27,475,000		21,087,000
Long-term deferred revenue	11,698,000		11,698,000		19,936,000
Regents Exclusive License Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future development and regulatory milestone payments	27,700,000		27,700,000
Future commercial milestone payments	3,600,000		3,600,000
Research and development expenses		400,000	400,000	400,000
Milestones			0		0
Accrued and other current liabilities	100,000		100,000
Royalties			0		0
Regents Exclusive License Agreements \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses	100,000
Acuitas Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future development and regulatory milestone payments	20,000,000		20,000,000
Future commercial milestone payments	40,000,000		40,000,000
Research and development expenses	2,000,000	100,000		500,000
Milestones			0		0
Accrued and other current liabilities	2,100,000		2,100,000
Acuitas Agreements \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses			2,000,000
Prevail License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses			31,000,000		31,000,000
Revenue	1,900,000	4,800,000	4,200,000	21,600,000
Short-term deferred revenue	10,600,000		10,600,000
Additional milestones			0		0
Prevail License Agreement \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development milestones receivable	110,000,000		110,000,000
Commercial milestones receivable	1,100,000,000		1,100,000,000
Sanofi Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	120,000	0	455,000
Sanofi Agreements \| 2022 License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	0	0	0
Development regulatory and commercial milestones	0		0		$ 0
Sanofi Agreements \| 2023 License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones	0	0	0	0
Revenue	0	$ 100,000	0	$ 500,000
Short-term deferred revenue	16,800,000		16,800,000
Long-term deferred revenue	$ 11,700,000		$ 11,700,000

Government Grants

6 Months Ended

Jun. 30, 2026

Government Assistance [Abstract]

Government Grants

7. Government Grants

In May and June 2026, the Company entered into Notices of Award with the California Institute for Regenerative Medicine, or CIRM, for preclinical development funding for the Company’s STX-1400 and STX-1200 programs, respectively. The awards provide for aggregate CIRM funding commitments of approximately $25.7 million, consisting of approximately $13.0 million for STX-1400 and approximately $12.7 million for STX-1200, subject to the achievement of specified operational milestones, compliance with reporting requirements, availability of CIRM funds and other conditions. The awards have estimated project periods extending from April 2026 through September 2029 for the STX-1400 program and from April 2026 through March 2029 for the STX-1200 program. The Company is also required to provide aggregate co-funding of approximately $7.1 million from non-CIRM sources.

The CIRM awards include 5% holdback payments that are payable only upon CIRM’s receipt and approval of specified final reporting requirements. The awards also include reporting, operational milestone, intellectual property, access, affordability and revenue sharing provisions applicable to CIRM-funded technology. Under the terms of the awards, the Company may be required to make future revenue sharing payments and royalties on commercial sales of products developed using CIRM-funded technology, generally at low single-digit percentage rates. Certain intellectual property, access, affordability and revenue sharing obligations may continue beyond the project periods specified in the award agreements. As of June 30, 2026, the Company had not recognized any receivable or grant income related to the holdback amounts because the related conditions had not been satisfied.

During the three and six months ended June 30, 2026, the Company received initial CIRM disbursements of approximately $3.8 million. Amounts recognized in earnings were recorded as a reduction of research and development expense, while amounts received in advance of qualifying expenditures were recorded as a government grant liability. As of June 30, 2026, the Company recorded a government grant liability of approximately $1.8 million within accrued expenses and other current liabilities for amounts received in advance of qualifying expenditures.

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2026

Accounting Policies [Abstract]

Schedule of Company Recognized Revenue From Collaboration Partners


	Accounts Receivable, net						Revenue						Revenue
	As of June 30,			As of December 31,			Three Months Ended June 30,						For the Six Months Ended June 30,
	2026			2025			2026			2025			2026			2025
Prevail		96	%		98	%		100	%		98	%		100	%		98	%

Redeemable Convertible Preferred Stock (Tables)

6 Months Ended

Jun. 30, 2026

Temporary Equity Disclosure [Abstract]

Schedule of Redeemable Convertible Preferred Stock

Redeemable convertible preferred stock consists of the following (in thousands, except share and per share amounts):


	December 31, 2025 and June 30, 2026
	Shares Authorized		Original Issue Price		Shares Issued and Outstanding		Carrying Value		Liquidation Preference
Series A		12,150,003	$	9.77		2,051,741	$	19,869	$	20,000
Series A-1		155,977		7.82		26,338		205		205
Series A-2		276,138		10.72		46,630		500		500
Series B		16,600,000		35.83		2,790,590		99,782		100,000
Total		29,182,118				4,915,299		120,356		120,705

Marketable Securities - Schedule of Fair Values of Available-for-Sale Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value [Abstract]
Due in 1 year or less	$ 7,423	$ 45,167
Due in 1 - 2 years	0	0
Due in 3 years	0	0
Instruments not due at a single maturity date	35,508	12,695
Total available-for-sale securities	$ 42,931	$ 57,862

Business Organization and Liquidity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended				6 Months Ended
	Jul. 27, 2026	Jul. 17, 2026	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash, cash equivalents and available-for-sale investments			$ 43,000				$ 43,000		$ 58,000
Net Loss			6,477	$ 17,347	$ 9,903	$ 3,425	23,824	$ 13,328
Accumulated deficit			$ (181,531)				$ (181,531)		$ (157,707)
Initial Public Offering
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of common stock (in shares)	9,867,000
Underwriters of their option to purchase	1,287,000
Offering price	$ 15
Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of common stock (in shares)	9,867,000
Underwriters of their option to purchase	1,287,000
Aggregate gross proceeds from the initial public offering	$ 148,000
Aggregate gross proceeds	7,500
IPO and concurrent private placement	155,500
Net proceeds	$ 140,700
Subsequent Event \| Private Placement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of common stock (in shares)	500,000	500,000
Offering price	$ 15

Fair Value Measurements - Schedule of Reconciliation of Beginning and Ending Balances of Convertible Note Fair Value (Details) - Convertible Note - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2026
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value at the beginning of the period	$ 40,546	$ 35,339
Accrued stated interest	276	875
Change in fair value of Convertible Note	(3,023)	1,585
Fair value at end of period	$ 37,799	$ 37,799

Marketable Securities - Schedule of Fair Value and Amortized Cost of Cash Equivalents and Available-for-Sale Investments by Major Security Type (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	$ 42,932	$ 57,827
Unrealized Gains	1	35
Unrealized Losses	(2)	0
Fair Value	42,931	57,862
Short-term Investments
Debt Securities, Available-for-Sale [Line Items]
Fair Value	7,423	45,167
Money Market Funds
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	35,508	12,695
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	35,508	12,695
US Treasury Securities
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	7,424	45,132
Unrealized Gains	1	35
Unrealized Losses	(2)	0
Fair Value	7,423	45,167
Cash Equivalents
Debt Securities, Available-for-Sale [Line Items]
Fair Value	$ 35,508	$ 12,695

Fair Value Measurements - Additional Information (Details)		6 Months Ended	12 Months Ended
	May 11, 2023	Jun. 30, 2026	Dec. 31, 2025
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Conversion event ranged, description	At issuance on May 11, 2023, the time to a conversion event ranged from 0.22 to 0.39 years and the discount rate applied was 29.1%.		On December 31, 2025, the time to event ranged from 0.25 to 0.36 years, and the discount rate applied was 27.55%.
Convertible note discount rate	29.10%		27.55%
Convertible note matured		May 11, 2026

Collaboration and License Agreements - Summary of Contract Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Beginning Balance	$ 41,023	$ 72,419
Additions	0	0
Revenue Recognized	(1,850)	(11,880)
Ending Balance	$ 39,173	$ 60,539

Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Balance Sheet Related Disclosures [Abstract]
Prepaid expenses	$ 865	$ 1,621
Accrued interest	104	240
Other receivables	20	18
Total	$ 989	$ 1,879

Equity Incentive Plan and Stock-Based Compensation - Schedule of Estimated Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected volatility, minimum	84.56%	85.54%
Expected volatility, maximum	88.16%	86.74%
Risk-free interest rate, minimum	3.87%	4.06%
Risk-free interest rate, maximum	4.17%	4.11%
Dividend yield	0.00%	0.00%
Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term	4 years 11 months 26 days	5 years 11 months 19 days
Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term	6 years 3 days	6 years 29 days

Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2026	Mar. 31, 2026	Dec. 31, 2025	Jun. 30, 2025	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2021	Jan. 31, 2019	Oct. 31, 2018
Temporary Equity [Line Items]
Carrying Value	$ 120,356		$ 120,356
Series A
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized	12,150,003		12,150,003
Original Issue Price	$ 9.77		$ 9.77						$ 9.77
Temporary Equity, Shares Issued	2,051,741		2,051,741						2,051,741
Temporary Equity, Shares Outstanding	2,051,741		2,051,741
Carrying Value	$ 19,869		$ 19,869
Liquidation Preference	$ 20,000		$ 20,000
Series A - 1
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized	155,977		155,977
Original Issue Price	$ 7.82		$ 7.82
Temporary Equity, Shares Issued	26,338		26,338						26,338
Temporary Equity, Shares Outstanding	26,338		26,338
Carrying Value	$ 205		$ 205
Liquidation Preference	$ 205		$ 205
Series A - 2
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized	276,138		276,138
Original Issue Price	$ 10.72		$ 10.72					$ 10.72
Temporary Equity, Shares Issued	46,630		46,630					46,630
Temporary Equity, Shares Outstanding	46,630		46,630
Carrying Value	$ 500		$ 500
Liquidation Preference	$ 500		$ 500
Series B
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized	16,600,000		16,600,000
Original Issue Price	$ 35.83		$ 35.83				$ 35.83
Temporary Equity, Shares Issued	2,790,590		2,790,590				2,790,590
Temporary Equity, Shares Outstanding	2,790,590		2,790,590
Carrying Value	$ 99,782		$ 99,782
Liquidation Preference	$ 100,000		$ 100,000
Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized	29,182,118		29,182,118
Original Issue Price	$ 0.001		$ 0.001
Temporary Equity, Shares Issued	4,915,299		4,915,299
Temporary Equity, Shares Outstanding	4,915,299	4,915,299	4,915,299	4,915,299	4,915,299	4,915,299
Carrying Value	$ 120,356	$ 120,356	$ 120,356	$ 120,356	$ 120,356	$ 120,356
Liquidation Preference	$ 120,705		$ 120,705

Equity Incentive Plan and Stock-Based Compensation - Additional Information (Details) - USD ($)			3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 26, 2026	Oct. 06, 2021	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock reserved for issuance			6,336,682		6,336,682		6,370,765
Stock-based compensation expense					$ 2,197,000	$ 1,347,000
Granted performance-based stock option awards					99,340
Employee Stock Option Member
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average grant date fair value per share of stock options granted					$ 20.98	$ 5.87
Intrinsic value of stock					$ 400,000
Option, costs not yet recognized			$ 2,700,000		$ 2,700,000
Remaining weighted-average period					1 year 2 months 19 days
Restricted Stock Award Activity
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock awards issued, non-employee consultants					48,021		48,021
Restricted stock awards outstanding, non-employee consultants			48,021		48,021		48,021
Weighted-average grant-date fair value of outstanding restricted stock awards (RSAs)					$ 2.84
Number of nonvested shares			0		0		0
Stock-based compensation expense			$ 0	$ 0	$ 0	$ 0
2018 Stock Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock reserved for issuance			1,672,540		1,672,540
Option granted description					Options under the Plan may be granted for periods of up to ten years and at prices based upon the estimated fair value of the shares on the date of grant as determined by the Board of Directors, provided, however, that (i) the exercise price of an option shall not be less than 100% of the estimated fair value of the shares on the date of grant, (ii) the exercise price of an ISO granted to a greater than 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant, and (iii) the term of an ISO granted to a greater than 10% stockholder should not exceed five years. Options granted generally vest over four years.
Vesting percentage					25.00%
Share-based payment award, expiration period					10 years
Share based compensation, contractual term					5 years
Share-based payment , vesting period					4 years
2018 Stock Incentive Plan \| Performance-Based Stock Option Awards \| Chief Executive Officer
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted performance-based stock option awards		101,320
2018 Stock Incentive Plan \| Performance-Based Stock Option Awards \| Chief Operating Officer
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted performance-based stock option awards	13,239

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2026	Aug. 31, 2026
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2026
Document Transition Report	false
Entity File Number	001-43409
Entity Registrant Name	SCRIBE THERAPEUTICS INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2157847
Entity Address, Address Line One	1150 Marina Village Parkway
Entity Address, City or Town	Alameda
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94501
City Area Code	(510)
Local Phone Number	626-8587
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	SCTX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,931,680
Entity Central Index Key	0001853921
Amendment Flag	false
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31

Government Grants - Additional Information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2026 USD ($)
Location, Statement of Financial Position, Activity, Accrual [Axis]: us-gaap:AccruedLiabilitiesAndOtherLiabilities
Government Assistance [Line Items]
Government grant liabilities	$ 1.8
CIRM
Government Assistance [Line Items]
Aggregate CIRM funding amount	$ 25.7
Percentage of holdback payments	5.00%
Initial distribution amount of CIRM	$ 3.8
Non-CIRM
Government Assistance [Line Items]
Aggregate Co-Funding Amount	7.1
STX-1400
Government Assistance [Line Items]
Aggregate CIRM funding amount	13.0
STX-1200
Government Assistance [Line Items]
Aggregate CIRM funding amount	$ 12.7

Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Property, Plant, and Equipment [Line Items]
Total	$ 17,946	$ 17,935
Less: Accumulated depreciation and amortization	(12,191)	(10,927)
Property and equipment, net	5,755	7,008
Laboratory Equipment
Property, Plant, and Equipment [Line Items]
Total	11,773	11,768
Leasehold Improvements
Property, Plant, and Equipment [Line Items]
Total	4,942	4,939
Computer Equipment and Software
Property, Plant, and Equipment [Line Items]
Total	906	903
Furniture and Office equipment
Property, Plant, and Equipment [Line Items]
Total	$ 325	$ 325

Segment Information - Additional Information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2026 USD ($) Segment	Dec. 31, 2025 USD ($)
Segment Reporting [Line Items]
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	Chief Executive Officer
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description	The Company’s chief executive officer serves as the chief operating decision maker (“CODM”). The CODM evaluates segment performance and allocates resources based on net loss and operating expenses, which are also reported in the statement of operations.
Total cash, cash equivalents and available-for-sale investments \| $	$ 43.0	$ 58.0
Single Reporting Segment
Segment Reporting [Line Items]
Number of reportable segments	1
Number of operating segments	1

Commitments and Contingencies - Additional Information (Details) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Commitments and Contingencies Disclosure [Abstract]
Research and development agreements, termination and cancellation charges accrual	$ 0	$ 0
Contingent milestones due and payable	$ 0	$ 0

Subsequent Events - Additional Information (Details) $ / shares in Units, $ in Millions				6 Months Ended
	Jul. 27, 2026 USD ($) $ / shares shares	Jul. 23, 2026 $ / shares shares	Jul. 17, 2026 $ / shares shares	Jun. 30, 2026 shares	Dec. 31, 2025 shares
Subsequent Event [Line Items]
Stock reserved for issuance				6,336,682	6,370,765
Stock options grant in period				99,340
Initial Public Offering
Subsequent Event [Line Items]
Issuance of common stock (in shares)	9,867,000
Underwriters of their option to purchase	1,287,000
Subsequent Event
Subsequent Event [Line Items]
Reverse stock split ratio			5.9218
Issuance of common stock (in shares)	9,867,000
Underwriters of their option to purchase	1,287,000
Aggregate gross proceeds \| $	$ 7.5
IPO and concurrent private placement \| $	$ 155.5
Subsequent Event \| Initial Public Offering
Subsequent Event [Line Items]
Offering price \| $ / shares	$ 15	$ 15	$ 15
Subsequent Event \| Private Placement
Subsequent Event [Line Items]
Issuance of common stock (in shares)	500,000		500,000
Subsequent Event \| Board of Directors
Subsequent Event [Line Items]
Stock options grant in period		2,066,997
Subsequent Event \| 2026 Equity Incentive Plan
Subsequent Event [Line Items]
Stock reserved for issuance		2,420,000

Common Stock - Additional Information (Details) - $ / shares	1 Months Ended
	Sep. 30, 2018	Aug. 31, 2018	Jan. 31, 2018	Jun. 30, 2026	Dec. 31, 2025
Class of Stock [Line Items]
Common stock, shares authorized				52,000,000	52,000,000
Common stock, par value				$ 0.001	$ 0.001
Restricted Common Stock
Class of Stock [Line Items]
Restricted common stock shares issued		2,195,278	2,195,278
Purchase price		$ 0.00592	$ 0.00592
Common stock repurchased	211,084

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 35,586	$ 12,796
Short-term investments	7,423	45,167
Receivable from collaboration partners	1,107	7,092
Prepaid expenses and other current assets	989	1,879
Total current assets	45,105	66,934
Operating lease right-of-use asset	2,782	3,064
Property and equipment, net	5,755	7,008
Restricted cash	675	675
Other long-term assets	3,610	538
Total assets	57,927	78,219
Current liabilities:
Accounts payable	2,771	4,566
Accrued expenses and other current liabilities	7,183	6,405
Accrued license fees	2,100	375
Deferred revenue, current	27,475	21,087
Convertible Note	37,799	35,339
Operating lease liabilities, current portion	1,369	1,285
Total current liabilities	78,697	69,057
Operating lease liabilities, net of current portion	4,102	4,804
Other non-current liabilities	7,920	7,485
Deferred revenue, non-current	11,698	19,936
Total liabilities	102,417	101,282
Redeemable convertible preferred stock, $0.001 par value; 29,182,118 shares authorized, and 4,915,299 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; liquidation preference of $120,705 as of June 30, 2026 and December 31, 2025	120,356	120,356
Common stock, $0.001 par value, 52,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 2,485,234 and 2,451,167 shares issued and outstanding as of June 30, 2026 and December 31, 2025	14	14
Additional paid-in capital	16,673	14,239
Accumulated deficit	(181,531)	(157,707)
Accumulated other comprehensive income	(2)	35
Total stockholders' deficit	(164,846)	(143,419)
Total liabilities, preferred stock, and stockholders' deficit	57,927	78,219
Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred stock, $0.001 par value; 29,182,118 shares authorized, and 4,915,299 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; liquidation preference of $120,705 as of June 30, 2026 and December 31, 2025	$ 120,356	$ 120,356

Equity Incentive Plan and Stock-Based Compensation - Schedule of Stock Option Activity (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2026 USD ($) $ / shares shares	Dec. 31, 2025 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of shares available for grant, beginning balance	152,545
Number of shares available for grant, granted	(99,340)
Number of shares available for grant, forfeited or cancelled	176,870
Number of shares available for grant, ending balance	230,075	152,545
Options issued and outstanding, beginning balance	1,180,576
Options issued and outstanding, granted	99,340
Options issued and outstanding, exercised	(34,083)
Options issued and outstanding, forfeited or cancelled	(176,870)
Options issued and outstanding, ending balance	1,068,963	1,180,576
Options issued and outstanding, vested and exercisable	808,434
Weighted average exercise price, outstanding at beginning balance \| $ / shares	$ 6.28
Weighted average exercise price, options granted \| $ / shares	19.13
Weighted average exercise price, options exercised \| $ / shares	6.62
Weighted average exercise price, options forfeited or cancelled \| $ / shares	7.61
Weighted average exercise price, outstanding at ending balance \| $ / shares	7.24	$ 6.28
Weighted average exercise price, vested and exercisable \| $ / shares	$ 7.21
Weighted average remaining contractual term (in years)	6 years 3 months	6 years 6 months 25 days
Aggregate intrinsic value \| $	$ 12,708	$ 896

Fair Value Measurements - Schedule of Financial Assets and Financial Liabilities Recognized at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total financial Assets	$ 42,931	$ 57,862
Total financial liabilities	37,799	35,339
Level 1
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total financial Assets	35,508	12,695
Level 2
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total financial Assets	7,423	45,167
Level 3
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total financial liabilities	37,799	35,339
Money Market Funds
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total financial Assets	35,508	12,695
Money Market Funds \| Level 1
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total financial Assets	35,508	12,695
US Treasury Securities
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total financial Assets	7,423	45,167
US Treasury Securities \| Level 2
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total financial Assets	7,423	45,167
Convertible Note
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total financial liabilities	37,799	35,339
Convertible Note \| Level 3
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total financial liabilities	$ 37,799	$ 35,339

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
us-gaap:NetIncomeLoss	$ (23,824)	$ (13,328)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	1,277	1,468
Loss on disposal of equipment	4	5
Stock-based compensation expense	2,197	1,347
Interest expense	875	1,197
Change in fair value of convertible note	1,585	(2,083)
Net amortization/accretion on investment securities	210	474
Amortization of right-of-use asset	281	230
Expensed deferred offering costs	0	3,583
Cash received from government grants	3,830	0
Changes in operating assets and liabilities:
Receivables from collaboration partners	5,985	292
Prepaid expenses and other current assets	890	445
Other long-term assets	(520)	(209)
Accounts payable	(2,139)	1,193
Deferred revenue	(1,850)	(11,880)
Accrued license fees	1,725	(750)
Accruals and other current liabilities	(3,236)	(479)
Operating lease liabilities	(616)	(531)
Other non-current liabilities	434	(1,226)
Net cash used in operating activities	(12,892)	(20,252)
Cash flows from investing activities
Purchases of property and equipment	(27)	(930)
Maturities of investments	42,339	56,231
Purchases of investments	(4,842)	(31,722)
Net cash provided by investing activities	37,470	23,579
Cash flows from financing activities
Proceeds from exercise of stock options	238	51
Payments of deferred offering costs	(2,026)	0
Net cash (used in) / provided by financing activities	(1,788)	51
Net change in cash, cash equivalents and restricted cash	22,790	3,378
Cash, cash equivalents and restricted cash, at the beginning of the period	13,471	13,277
Cash, cash equivalents and restricted cash, at the end of the period	36,261	16,655
Supplemental disclosure of non-cash investing and financing activities:
Unpaid fixed asset acquisitions	0	306
Deferred offering costs related to initial public offering included in accounts payable and accrued expenses and other current liabilities	$ 975	$ 0

CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT (Unaudited) - USD ($) $ in Thousands	Total	Redeemable Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance, Shares at Dec. 31, 2024			2,417,435
Beginning Balance, Shares at Dec. 31, 2024		4,915,299
Beginning Balance, Amount at Dec. 31, 2024	$ (125,859)		$ 14	$ 9,954	$ 72	$ (135,899)
Beginning Balance, Amount at Dec. 31, 2024		$ 120,356
Stock-based compensation expense	671			671
us-gaap:NetIncomeLoss	(3,425)					(3,425)
Net unrealized loss on available-for-sale investments	(57)				(57)
Ending Balance, Shares at Mar. 31, 2025			2,417,435
Ending Balance, Shares at Mar. 31, 2025		4,915,299
Ending Balance, Amount at Mar. 31, 2025	(128,670)		$ 14	10,625	15	(139,324)
Ending Balance, Amount at Mar. 31, 2025		$ 120,356
Beginning Balance, Shares at Dec. 31, 2024			2,417,435
Beginning Balance, Shares at Dec. 31, 2024		4,915,299
Beginning Balance, Amount at Dec. 31, 2024	(125,859)		$ 14	9,954	72	(135,899)
Beginning Balance, Amount at Dec. 31, 2024		$ 120,356
us-gaap:NetIncomeLoss	(13,328)
Net unrealized loss on available-for-sale investments	(93)
Ending Balance, Shares at Jun. 30, 2025			2,430,956
Ending Balance, Shares at Jun. 30, 2025		4,915,299
Ending Balance, Amount at Jun. 30, 2025	(137,882)		$ 14	11,352	(21)	(149,227)
Ending Balance, Amount at Jun. 30, 2025		$ 120,356
Beginning Balance, Shares at Mar. 31, 2025			2,417,435
Beginning Balance, Shares at Mar. 31, 2025		4,915,299
Beginning Balance, Amount at Mar. 31, 2025	(128,670)		$ 14	10,625	15	(139,324)
Beginning Balance, Amount at Mar. 31, 2025		$ 120,356
Issuance of common stock upon exercise of stock options, Shares			13,521
Issuance of common stock upon exercise of stock options, Amount	51			51
Stock-based compensation expense	676			676
us-gaap:NetIncomeLoss	(9,903)					(9,903)
Net unrealized loss on available-for-sale investments	(36)				(36)
Ending Balance, Shares at Jun. 30, 2025			2,430,956
Ending Balance, Shares at Jun. 30, 2025		4,915,299
Ending Balance, Amount at Jun. 30, 2025	(137,882)		$ 14	11,352	(21)	(149,227)
Ending Balance, Amount at Jun. 30, 2025		$ 120,356
Beginning Balance, Shares at Dec. 31, 2025			2,451,167
Beginning Balance, Shares at Dec. 31, 2025		4,915,299
Beginning Balance, Amount at Dec. 31, 2025	(143,419)		$ 14	14,239	35	(157,707)
Beginning Balance, Amount at Dec. 31, 2025	120,356	$ 120,356
Issuance of common stock upon exercise of stock options, Shares			17,026
Issuance of common stock upon exercise of stock options, Amount	93			93
Stock-based compensation expense	1,970			1,970
us-gaap:NetIncomeLoss	(17,347)					(17,347)
Net unrealized loss on available-for-sale investments	(35)				(35)
Ending Balance, Shares at Mar. 31, 2026			2,468,193
Ending Balance, Shares at Mar. 31, 2026		4,915,299
Ending Balance, Amount at Mar. 31, 2026	(158,738)		$ 14	16,302	0	(175,054)
Ending Balance, Amount at Mar. 31, 2026		$ 120,356
Beginning Balance, Shares at Dec. 31, 2025			2,451,167
Beginning Balance, Shares at Dec. 31, 2025		4,915,299
Beginning Balance, Amount at Dec. 31, 2025	(143,419)		$ 14	14,239	35	(157,707)
Beginning Balance, Amount at Dec. 31, 2025	120,356	$ 120,356
us-gaap:NetIncomeLoss	(23,824)
Net unrealized loss on available-for-sale investments	(37)
Ending Balance, Shares at Jun. 30, 2026			2,485,234
Ending Balance, Shares at Jun. 30, 2026		4,915,299
Ending Balance, Amount at Jun. 30, 2026	(164,846)		$ 14	16,673	(2)	(181,531)
Ending Balance, Amount at Jun. 30, 2026	120,356	$ 120,356
Beginning Balance, Shares at Mar. 31, 2026			2,468,193
Beginning Balance, Shares at Mar. 31, 2026		4,915,299
Beginning Balance, Amount at Mar. 31, 2026	(158,738)		$ 14	16,302	0	(175,054)
Beginning Balance, Amount at Mar. 31, 2026		$ 120,356
Issuance of common stock upon exercise of stock options, Shares			17,041
Issuance of common stock upon exercise of stock options, Amount	144			144
Stock-based compensation expense	227			227
us-gaap:NetIncomeLoss	(6,477)					(6,477)
Net unrealized loss on available-for-sale investments	(2)				(2)
Ending Balance, Shares at Jun. 30, 2026			2,485,234
Ending Balance, Shares at Jun. 30, 2026		4,915,299
Ending Balance, Amount at Jun. 30, 2026	(164,846)		$ 14	$ 16,673	$ (2)	$ (181,531)
Ending Balance, Amount at Jun. 30, 2026	$ 120,356	$ 120,356

Common Stock - Schedule of Reserved Common Stock for Future Issuance (Details) - shares	Jun. 30, 2026	Dec. 31, 2025
Class of Stock [Line Items]
Total common stock reserved	6,336,682	6,370,765
Conversion of redeemable convertible preferred stock
Class of Stock [Line Items]
Total common stock reserved	4,915,299	4,915,299
Exercise of outstanding stock option awards
Class of Stock [Line Items]
Total common stock reserved	1,068,963	1,180,576
Common Stock Warrants issued and outstanding
Class of Stock [Line Items]
Total common stock reserved	74,324	74,324
Restricted stock issued and outstanding
Class of Stock [Line Items]
Total common stock reserved	48,021	48,021
Stock options available for future grant
Class of Stock [Line Items]
Total common stock reserved	230,075	152,545